OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
RHC58

RHC.AX

Healthcare Facilities & ServicesVerified

RHC.AX has a debt-to-equity ratio of 2.41, indicating a significant reliance on debt financing, which is higher than the typical industry median for healthcare facilities and services. The company's liquidity position is characterized as medium, with a current ratio of 0.9, suggesting that it may struggle to meet short-term obligations without additional financing. Profitability metrics for RHC.AX are weak, with a return on equity of 0.48% and a return on assets of 0.11%. These figures are below the industry benchmarks, indicating that the company is not effectively utilizing its equity and assets to generate returns. The net income of 24 million AUD is also significantly lower than the operating income of 707.7 million AUD, highlighting the presence of substantial non-operating expenses or losses. The company's revenue is primarily concentrated in its domestic market, with no significant international operations disclosed. This concentration increases the company's exposure to local economic conditions and regulatory changes. The lack of geographic diversification is a notable risk factor, especially in a sector that is highly regulated and sensitive to policy changes. RHC.AX's growth trajectory is modest, with the company's revenue in the latest period standing at 1.78 billion AUD. While the company has a positive operating cash flow of 1.48 billion AUD, the free cash flow is only 217.2 million AUD, which is insufficient to cover the capital expenditures of 776.6 million AUD. This suggests that the company may need to rely on external financing to fund its capital needs, which could increase its debt burden and financial risk. The risk assessment for RHC.AX indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could limit its ability to respond to unexpected financial needs. The low dilution risk is attributed to the absence of significant dilution sources in the recent filings and the stable number of shares outstanding. Recent events and filings for RHC.AX include the latest financial results, which show a decline in net income despite a relatively stable revenue. The company's management has not disclosed any major strategic initiatives or new product launches in the recent transcripts, which may indicate a lack of growth drivers. The analyst estimates suggest a mixed outlook, with a mean price target of 42.60 AUD and a median price target of 43.15 AUD, reflecting cautious optimism among analysts.

30-day price · RHC-4.21 (-10.2%)
Low$35.82High$42.74Close$37.00As of28 May, 00:00 UTC
Profile
CompanyRHC.AX
TickerRHC.AX
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. RHC.AX operates in the healthcare sector, providing pharmaceutical products and services, primarily through its operations in Australia.

Classification. RHC.AX is classified under the Healthcare Facilities & Services industry within the Healthcare Services & Equipment business sector, with a classification confidence of 0.92.

RHC.AX has a debt-to-equity ratio of 2.41, indicating a significant reliance on debt financing, which is higher than the typical industry median for healthcare facilities and services. The company's liquidity position is characterized as medium, with a current ratio of 0.9, suggesting that it may struggle to meet short-term obligations without additional financing. Profitability metrics for RHC.AX are weak, with a return on equity of 0.48% and a return on assets of 0.11%. These figures are below the industry benchmarks, indicating that the company is not effectively utilizing its equity and assets to generate returns. The net income of 24 million AUD is also significantly lower than the operating income of 707.7 million AUD, highlighting the presence of substantial non-operating expenses or losses. The company's revenue is primarily concentrated in its domestic market, with no significant international operations disclosed. This concentration increases the company's exposure to local economic conditions and regulatory changes. The lack of geographic diversification is a notable risk factor, especially in a sector that is highly regulated and sensitive to policy changes. RHC.AX's growth trajectory is modest, with the company's revenue in the latest period standing at 1.78 billion AUD. While the company has a positive operating cash flow of 1.48 billion AUD, the free cash flow is only 217.2 million AUD, which is insufficient to cover the capital expenditures of 776.6 million AUD. This suggests that the company may need to rely on external financing to fund its capital needs, which could increase its debt burden and financial risk. The risk assessment for RHC.AX indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could limit its ability to respond to unexpected financial needs. The low dilution risk is attributed to the absence of significant dilution sources in the recent filings and the stable number of shares outstanding. Recent events and filings for RHC.AX include the latest financial results, which show a decline in net income despite a relatively stable revenue. The company's management has not disclosed any major strategic initiatives or new product launches in the recent transcripts, which may indicate a lack of growth drivers. The analyst estimates suggest a mixed outlook, with a mean price target of 42.60 AUD and a median price target of 43.15 AUD, reflecting cautious optimism among analysts.
Key takeaways
  • RHC.AX has a high debt-to-equity ratio of 2.41, indicating a significant reliance on debt financing.
  • The company's profitability metrics, such as return on equity and return on assets, are below industry benchmarks.
  • RHC.AX's revenue is primarily concentrated in its domestic market, increasing its exposure to local economic and regulatory conditions.
  • The company's free cash flow is insufficient to cover its capital expenditures, suggesting a need for external financing.
  • Analysts have a mixed outlook on RHC.AX, with a mean price target of 42.60 AUD and a median price target of 43.15 AUD.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyAUD
Revenue$17.81B
Gross profit$13.17B
Operating income$707.7M
Net income$24.0M
R&D
SG&A
D&A
SBC
Operating cash flow$1.48B
CapEx-$776.6M
Free cash flow$217.2M
Total assets$22.48B
Total liabilities$17.45B
Total equity$5.02B
Cash & equivalents$784.4M
Long-term debt$12.12B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$5.02B
Net cash-$11.34B
Current ratio0.9
Debt/Equity2.4
ROA0.1%
ROE0.5%
Cash conversion61.7%
CapEx/Revenue-4.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricRHCActivity
Op margin4.0%7.7% medp25 -2.4% · p75 15.5%below median
Net margin0.1%5.9% medp25 -3.8% · p75 12.8%below median
Gross margin74.0%45.5% medp25 31.1% · p75 62.9%top quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-4.4%-7.0% medp25 -14.9% · p75 -3.2%above median
Debt / equity241.0%25.0% medp25 3.8% · p75 63.3%top quartile
Observations
IR observations
Mean price target42.60 AUD
Median price target43.15 AUD
High price target47.80 AUD
Low price target35.60 AUD
Mean recommendation2.80 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count4.00
Hold count10.00
Sell count1.00
Strong-sell count0.00
Mean EPS estimate1.35 AUD
Last actual EPS1.33 AUD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-06 16:47 UTC#8014497c
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 05:04 UTCJob: c02f3bdc